[1] Muramatsu T, Kadomatsu K. Midkine:an emerging target of drug development for treatment of multiple diseases[J]. Br J Pharmacol, 2014, 171(4):811-813. DOI:10.1111/bph.12571.
[2] Muramatsu T. Structure and function of midkine as the basis of its pharmacological effects[J]. Br J Pharmacol, 2014, 171(4):814-826. DOI:10.1111/bph.12353.
[3] Tian W, Shen J, Chen W. Suppression of midkine gene promotes the antitumoral effect of cisplatin on human gastric cancer cell line AGS in vitro and in vivo via the modulation of Notch signaling pathway[J]. Oncol Rep, 2017, 38(2):745-754. DOI:10.3892/or.2017. 5743.
[4] Zhu WW, Guo JJ, Guo L, et al. Evaluation of midkine as a diagnostic serum biomarker in hepatocellular carcinoma[J]. Clin Cancer Res, 2013, 19(14):3944-3954. DOI:10.1158/1078-0432.CCR-12-3363.
[5] Sun B, Hu C, Yang Z, et al. Midkine promotes hepatocellular carcinoma metastasis by elevating anoikis resistance of circulating tumor cells[J]. Oncotarget, 2017, 8(20):32523-32535. DOI:10.18632/oncotarget.15808.
[6]

Vongsuvanh R, van der Poorten D, Iseli T, et al. Midkine Increases Diagnostic Yield in AFP Negative and NASH-Related Hepatocellular Carcinoma[J/OL]. PLoS One, 2016, 11(5): e0155800[2018-01-07]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC48-78793. DOI: 10.1371/journal.pone.0155800.
[7] Yamashita T, Shimada H, Tanaka S, et al. Serum midkine as a biomarker for malignancy, prognosis, and chemosensitivity in head and neck squamous cell carcinoma[J]. Cancer Med, 2016, 5(3):415-425. DOI:10.1002/cam4.600.
[8] Xia X, Lu JJ, Zhang SS, et al. Midkine is a serum and urinary biomarker for the detection and prognosis of non-small cell lung cancer[J]. Oncotarget, 2016, 7(52):87462-87472. DOI:10.18632/oncotarget.13865.
[9] Ak G, Tada Y, Shimada H, et al. Midkine is a potential novel marker for malignant mesothelioma with different prognostic and diagnostic values from mesothelin[J]. BMC Cancer, 2017, 17(1):212. DOI:10.1186/s12885-017-3209-5.
[10] Jones DR. Measuring midkine:the utility of midkine as a biomarker in cancer and other diseases[J]. Br J Pharmacol, 2014, 171(12):2925-2939. DOI:10.1111/bph.12601.
[11] Dianat N, Le VB, Gobbo E, et al. Midkine lacking its last 40 amino acids acts on endothelial and neuroblastoma tumor cells and inhibits tumor development[J]. Mol Cancer Ther, 2015, 14(1):213-224. DOI:10.1158/1535-7163.MCT-14-0226.
[12] Rawnaq T, Dietrich L, Wolters-Eisfeld G, et al. The multifunctional growth factor midkine promotes proliferation and migration in pancreatic cancer[J]. Mol Cancer Res, 2014, 12(5):670-680. DOI:10.1158/1541-7786. MCR-13-0467.
[13] Kato M, Maeta H, Kato S, et al. Immunohistochemical and in situ hybridization analyses of midkine expression in thyroid papillary carcinoma[J]. Mod Pathol, 2000, 13(10):1060-1065. DOI:10.1038/modpathol.3880195.
[14] Shao H, Yu X, Wang C, et al. Midkine expression is associated with clinicopathological features and BRAF mutation in papillary thyroid cancer[J]. Endocrine, 2014, 46(2):285-291. DOI:10.1007/s12020-013-0068-y.
[15] Choi YW, Kim YH, Lee J, et al. Strong immunoexpression of midkine is associated with multiple lymph node metastases in BRAFV600E papillary thyroid carcinoma[J]. Hum Pathol, 2015, 46(10):1557-1565. DOI:10.1016/j.humpath.2015.06.018.
[16] Zhang Y, Meng Z, Zhang M, et al. Immunohistochemical evaluation of midkine and nuclear factor-kappa B as diagnostic biomarkers for papillary thyroid cancer and synchronous metastasis[J]. Life Sci, 2014, 118(1):39-45. DOI:10.1016/j.lfs.2014.09.025.
[17] Jee YH, Celi FS, Sampson M, et al. Midkine concentrations in fine-needle aspiration of benign and malignant thyroid nodules[J]. Clin Endocrinol (Oxf), 2015, 83(6):977-984. DOI:10.1111/cen.12676.
[18] Kuzu F, Arpaci D, Unal M, et al. Midkine:A Novel Biomarker to Predict Malignancy in Patients with Nodular Thyroid Disease[J]. Int J Endocrinol, 2016, 2016:6035024[2018-01-07]. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4944023.DOI:10.1155/2016/6035024.
[19] Meng Z, Tan J, Zhang G, et al. Evaluation of serum midkine as a biomarker in differentiated thyroid cancer[J]. Life Sci, 2015, 130:18-24. DOI:10.1016/j.lfs.2015.02.028.
[20]

Jia Q, Meng Z, Xu K, et al. Serum midkine as a surrogate biomarker for metastatic prediction in differentiated thyroid cancer patients with positive thyroglobulin antibody[J/OL]. Sci Rep, 2017, 7: 43516[2018-01-07]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5378906. DOI: 10.1038/srep43516.
[21]

Jing X, Cui X, Liang H, et al. Diagnostic accuracy of ELISA for detecting serum Midkine in cancer patients[J/OL]. PLoS One, 2017, 12(7): e018051[2018-01-08]. https://www.ncbi.nlm.nih.gov/pubmed/28686647. DOI: 10.1371/journal.pone.0180511.
[22] Masui M, Okui T, Shimo T, et al. Novel Midkine Inhibitor iMDK Inhibits Tumor Growth and Angiogenesis in Oral Squamous Cell Carcinoma[J]. Anticancer Res, 2016, 36(6):2775-2781.
[23] Sun B, Hu C, Yang Z, et al. Midkine promotes hepatocellular carcinoma metastasis by elevating anoikis resistance of circulating tumor cells[J]. Oncotarget, 2017, 8(20):32523-32535. DOI:10.18632/oncotarget.15808.
[24] Ishida N, Fukazawa T, Maeda Y, et al. A novel PI3K inhibitor iMDK suppresses non-small cell lung Cancer cooperatively with A MEK inhibitor[J]. Exp Cell Res, 2015, 335(2):197-206. DOI:10.1016/j.yexcr.2015.03.019.
[25] Ho AL, Grewal RK, Leboeuf R, et al. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer[J]. N Engl J Med, 2013, 368(7):623-632. DOI:10.1056/NEJMoa1209288.